Pharsight

Drugs with Para IV expiring in 2023

1. Abilify Maintena Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759351 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(9 months ago)

US8338428 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(9 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-746) Jul 27, 2020
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

2. Afinitor Disperz patents expiration

Can you believe AFINITOR DISPERZ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617598

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Mar, 2023

(1 year, 2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-169) Apr 10, 2025
New Indication(I-773) Apr 10, 2021
Pediatric Exclusivity(PED) Apr 29, 2014
Orphan Drug Exclusivity(ODE) Oct 29, 2017
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
New Indication(I-630) Oct 29, 2013

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 29 April, 2017

Market Authorisation Date: 29 August, 2012

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of AFINITOR DISPERZ before it's drug patent expiration?
More Information on Dosage

AFINITOR DISPERZ family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Banzel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6740669

(Pediatric)

EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
May, 2023

(1 year, 17 days ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) May 14, 2016
New Chemical Entity Exclusivity(NCE) Nov 14, 2013
Orphan Drug Exclusivity(ODE) Nov 14, 2015

Drugs and Companies using RUFINAMIDE ingredient

NCE-1 date: 15 May, 2015

Market Authorisation Date: 03 March, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of BANZEL before it's drug patent expiration?
More Information on Dosage

BANZEL family patents

Family Patents

4. Belviq Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8367657 EISAI INC Processes for preparing 3-benzazepines
Apr, 2023

(1 year, 1 month ago)

US6953787 EISAI INC 5HT2C receptor modulators
Apr, 2023

(1 year, 1 month ago)

US8546379 EISAI INC 5HT2C receptor modulators
Apr, 2023

(1 year, 1 month ago)

US7977329 EISAI INC 5HT2C receptor modulators
Apr, 2023

(1 year, 1 month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8273734 EISAI INC 5HT2C receptor modulators
Apr, 2023

(1 year, 1 month ago)

US8207158 EISAI INC 5HT2c receptor modulators
Apr, 2023

(1 year, 1 month ago)

US8575149 EISAI INC 5HT2C receptor modulators
Apr, 2023

(1 year, 1 month ago)

US7514422 EISAI INC 5HT2c receptor modulators
Apr, 2023

(1 year, 1 month ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: Method for chronic weight management by controlling weight gain; Method for chronic weight management; Method for chronic weight management by treating obesity; Method for chronic weight management by...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage

BELVIQ XR family patents

Family Patents

5. Bethkis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696178 CHIESI Optimised formulation of tobramycin for aerosolization
Mar, 2023

(1 year, 2 months ago)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 12 October, 2012

Treatment: NA

Dosage: SOLUTION;INHALATION

How can I launch a generic of BETHKIS before it's drug patent expiration?
More Information on Dosage

BETHKIS family patents

Family Patents

6. Complera patents expiration

COMPLERA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(1 year, 1 month ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 13, 2016
New Chemical Entity Exclusivity(NCE) May 20, 2016

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 21 May, 2015

Market Authorisation Date: 10 August, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage

COMPLERA family patents

Family Patents

7. Dificid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8586551 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jul, 2023

(10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-367) Jan 24, 2027
New Patient Population(NPP) Jan 24, 2023
Pediatric Exclusivity(PED) Jul 24, 2023
New Chemical Entity Exclusivity(NCE) May 27, 2016

Drugs and Companies using FIDAXOMICIN ingredient

NCE-1 date: 24 July, 2022

Market Authorisation Date: 27 May, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage

DIFICID family patents

Family Patents

8. Dymista patents expiration

DYMISTA's oppositions filed in EPO
DYMISTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(11 months ago)

US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(11 months ago)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2023

(9 months ago)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Dec, 2023

(5 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Feb 20, 2018
Pediatric Exclusivity(PED) Aug 20, 2018
New Combination(NC) May 01, 2015

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: Treatment of seasonal allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of DYMISTA before it's drug patent expiration?
More Information on Dosage

DYMISTA family patents

Family Patents

9. Entresto patents expiration

ENTRESTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796331 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2023

(1 year, 4 months ago)

US8404744 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2023

(1 year, 4 months ago)

US8796331

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2023

(10 months ago)

US8404744

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2023

(10 months ago)

US7468390 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Nov, 2023

(6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-82) Feb 16, 2024
Pediatric Exclusivity(PED) Apr 01, 2023
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: Treatment of heart failure

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

10. Epiduo Forte patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8729127 GALDERMA LABS Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Mar, 2023

(1 year, 2 months ago)

US8703820 GALDERMA LABS Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Mar, 2023

(1 year, 2 months ago)

US9381179 GALDERMA LABS Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Mar, 2023

(1 year, 2 months ago)

US9387187 GALDERMA LABS Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Mar, 2023

(1 year, 2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 15, 2018

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 15 July, 2015

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of EPIDUO FORTE before it's drug patent expiration?
More Information on Dosage

EPIDUO FORTE family patents

Family Patents

11. Finacea patents expiration

FINACEA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722021 LEO PHARMA AS Foamable carriers
Oct, 2023

(7 months ago)

US10322085 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Oct, 2023

(7 months ago)

US8900554 LEO PHARMA AS Foamable composition and uses thereof
Oct, 2023

(7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 29, 2018

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: NA

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of FINACEA before it's drug patent expiration?
More Information on Dosage

FINACEA family patents

Family Patents

12. Glyxambi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-739) Dec 02, 2019
New Combination(NC) Jan 30, 2018
M(M-258) Jul 03, 2022
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-252) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

NCE-1 date: 01 August, 2018

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage

GLYXAMBI family patents

Family Patents

13. Hysingla Er patents expiration

HYSINGLA ER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675610 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(11 months ago)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(11 months ago)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(6 months ago)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(6 months ago)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HYSINGLA ER before it's drug patent expiration?
More Information on Dosage

HYSINGLA ER family patents

Family Patents

14. Ibrance patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7208489 PFIZER 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Jan, 2023

(1 year, 4 months ago)

US6936612 PFIZER 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
Jan, 2023

(1 year, 4 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456168 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
Jan, 2023

(1 year, 4 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-725) Feb 19, 2019
New Chemical Entity Exclusivity(NCE) Feb 03, 2020

Drugs and Companies using PALBOCICLIB ingredient

NCE-1 date: 03 February, 2019

Market Authorisation Date: 03 February, 2015

Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor in pts as initial endocrine-based therapy or with fulvestrant with disease progression after...

Dosage: CAPSULE;ORAL; TABLET;ORAL

How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage

IBRANCE family patents

Family Patents

15. Injectafer patents expiration

INJECTAFER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10519252 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(7 months ago)

US11590097 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(7 months ago)

US11291645 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(7 months ago)

US11123321 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(7 months ago)

US9376505 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-915) May 31, 2026
New Patient Population(NPP) Nov 19, 2024
New Strength(NS) Apr 28, 2024
New Product(NP) Jul 25, 2016

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 28 April, 2021

Treatment: A method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering ferric carboxymaltose to...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage

INJECTAFER family patents

Family Patents

16. Janumet Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873

(Pediatric)

MSD SUB MERCK Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 4 months ago)

US6699871

(Pediatric)

MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 4 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-187) Dec 04, 2023
Pediatric Exclusivity(PED) Feb 12, 2023
M(M-244) Aug 12, 2022

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 02 February, 2012

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JANUMET XR before it's drug patent expiration?
More Information on Dosage

JANUMET XR family patents

Family Patents

17. Jentadueto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-146) Jul 30, 2017
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022
New Combination(NC) Jan 30, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 30 January, 2012

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in co...

Dosage: TABLET;ORAL

How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage

JENTADUETO family patents

Family Patents

18. Jentadueto Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea; Method of treating type 2 diabetes melli...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage

JENTADUETO XR family patents

Family Patents

19. Juluca patents expiration

JULUCA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(1 year, 1 month ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 12, 2018
New Combination(NC) Nov 21, 2020

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 21 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage

JULUCA family patents

Family Patents

20. Kengreal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6130208 CHIESI Formulation containing a nucleotide analogue
Jun, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 22, 2020

Drugs and Companies using CANGRELOR ingredient

NCE-1 date: 23 June, 2019

Market Authorisation Date: 22 June, 2015

Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a ...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage

KENGREAL family patents

Family Patents

21. Kombiglyze Xr patents expiration

KOMBIGLYZE XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-134) May 24, 2016
M(M-175) Apr 05, 2019
M(M-198) Feb 27, 2020
New Chemical Entity Exclusivity(NCE) Jul 31, 2014

Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2013

Market Authorisation Date: 05 November, 2010

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of KOMBIGLYZE XR before it's drug patent expiration?
More Information on Dosage

KOMBIGLYZE XR family patents

Family Patents

22. Mektovi patents expiration

MEKTOVI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178693 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(1 year, 2 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8193229 ARRAY BIOPHARMA INC Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(1 year, 2 months ago)

US8513293 ARRAY BIOPHARMA INC Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal
Mar, 2023

(1 year, 2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026
New Chemical Entity Exclusivity(NCE) Jun 27, 2023

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage

MEKTOVI family patents

Family Patents

23. Myrbetriq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835474 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(6 months ago)

USRE44872 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(6 months ago)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(6 months ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(6 months ago)

US7750029 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Dec, 2023

(5 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-855) Mar 25, 2024
Pediatric Exclusivity(PED) Sep 25, 2024
New Indication(I-777) Apr 27, 2021
New Chemical Entity Exclusivity(NCE) Jun 28, 2017

Drugs and Companies using MIRABEGRON ingredient

NCE-1 date: 26 September, 2023

Market Authorisation Date: 28 June, 2012

Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Treatment of overactive bladder with symptoms of urge urinary incontinence, ur...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage

MYRBETRIQ family patents

Family Patents

24. Nucynta Er patents expiration

NUCYNTA ER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8075872 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(6 months ago)

US8309060 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(6 months ago)

US8420056 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Aug 25, 2014
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Indication(I-656) Aug 28, 2015

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 20 November, 2012

Market Authorisation Date: 25 August, 2011

Treatment: Relief of moderate to severe chronic pain

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage

NUCYNTA ER family patents

Family Patents

25. Nymalize patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070581 AZURITY Dispenser for medicaments and method and apparatus for making same
Jun, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-46) May 10, 2020
Orphan Drug Exclusivity(ODE) May 10, 2020

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of NYMALIZE before it's drug patent expiration?
More Information on Dosage

NYMALIZE family patents

Family Patents

26. Odefsey patents expiration

ODEFSEY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(1 year, 1 month ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
M(M-207) Aug 21, 2020
M(M-206) Aug 21, 2020

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 01 March, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage

ODEFSEY family patents

Family Patents

27. Omidria patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278101 RAYNER SURGICAL Ophthalmologic irrigation solutions and method
Jul, 2023

(10 months ago)

US8173707 RAYNER SURGICAL Ophthalmologic irrigation solutions and method
Jul, 2023

(10 months ago)

US8586633 RAYNER SURGICAL Ophthalmologic irrigation solutions and method
Jul, 2023

(10 months ago)

US9399040 RAYNER SURGICAL Ophthalmologic irrigation solutions and method
Jul, 2023

(10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 30, 2017
New Patient Population(NPP) Dec 08, 2020
Pediatric Exclusivity(PED) Jun 08, 2021

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 May, 2014

Treatment: Maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain

Dosage: SOLUTION;IRRIGATION

How can I launch a generic of OMIDRIA before it's drug patent expiration?
More Information on Dosage

OMIDRIA family patents

Family Patents

28. Otezla patents expiration

OTEZLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7893101 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Dec, 2023

(5 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455536 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
Mar, 2023

(1 year, 2 months ago)

US8802717 AMGEN INC Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
Mar, 2023

(1 year, 2 months ago)

US7208516 AMGEN INC Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Mar, 2023

(1 year, 2 months ago)

US7659302 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
Mar, 2023

(1 year, 2 months ago)

US9018243 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Mar, 2023

(1 year, 2 months ago)

US6962940 AMGEN INC (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
Mar, 2023

(1 year, 2 months ago)

US9724330 AMGEN INC Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Mar, 2023

(1 year, 2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-248) Jul 19, 2026
New Indication(I-884) Dec 20, 2024
M(M-299) Jul 20, 2026
New Chemical Entity Exclusivity(NCE) Mar 21, 2019
New Indication(I-694) Sep 23, 2017
New Indication(I-803) Jul 19, 2022
M(M-257) Apr 10, 2023

Drugs and Companies using APREMILAST ingredient

NCE-1 date: 21 March, 2018

Market Authorisation Date: 21 March, 2014

Treatment: Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriatic arthritis

Dosage: TABLET;ORAL

How can I launch a generic of OTEZLA before it's drug patent expiration?
More Information on Dosage

OTEZLA family patents

Family Patents

29. Oxaydo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7510726 ZYLA Methods and compositions for deterring abuse of opioid containing dosage forms
Nov, 2023

(6 months ago)

US7981439 ZYLA Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof
Nov, 2023

(6 months ago)

US8637540 ZYLA Compositions for deterring abuse of opioid containing dosage forms
Nov, 2023

(6 months ago)

US8409616 ZYLA Extended release opioid abuse deterrent compositions and methods of making same
Nov, 2023

(6 months ago)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of OXAYDO before it's drug patent expiration?
More Information on Dosage

OXAYDO family patents

Family Patents

30. Ozempic patents expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

OZEMPIC's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-185) Mar 28, 2025
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Indication(I-822) Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

31. Pomalyst patents expiration

POMALYST's oppositions filed in EPO
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673939 BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(1 year, 16 days ago)

US8735428 BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(1 year, 16 days ago)

US8673939

(Pediatric)

BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(6 months ago)

US8735428

(Pediatric)

BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-14) Nov 20, 2023
Orphan Drug Exclusivity(ODE-297) May 14, 2027
Orphan Drug Exclusivity(ODE-296) May 14, 2027
Pediatric Exclusivity(PED) Nov 14, 2027
New Indication(I-707) Apr 23, 2018
Orphan Drug Exclusivity(ODE-43) Feb 08, 2020
Orphan Drug Exclusivity(ODE) Feb 08, 2020
New Chemical Entity Exclusivity(NCE) Feb 08, 2018

Drugs and Companies using POMALIDOMIDE ingredient

NCE-1 date: 14 November, 2026

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on o...

Dosage: CAPSULE;ORAL

How can I launch a generic of POMALYST before it's drug patent expiration?
More Information on Dosage

POMALYST family patents

Family Patents

32. Prestalia patents expiration

PRESTALIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6696481 ADHERA Salt of perindopril and pharmaceutical compositions containing it
Apr, 2023

(1 year, 1 month ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 21, 2018

Drugs and Companies using AMLODIPINE BESYLATE; PERINDOPRIL ARGININE ingredient

Market Authorisation Date: 21 January, 2015

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of PRESTALIA before it's drug patent expiration?
More Information on Dosage

PRESTALIA family patents

Family Patents

33. Promacta Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics
May, 2023

(1 year, 11 days ago)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
May, 2023

(1 year, 10 days ago)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Nov, 2023

(6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Nov 16, 2025
New Dosing Schedule(D-149) Jun 11, 2018
New Indication(I-711) Jun 11, 2018
Orphan Drug Exclusivity(ODE) Aug 26, 2021
Pediatric Exclusivity(PED) Feb 26, 2022
Orphan Drug Exclusivity(ODE-74) Aug 26, 2021

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 27 September, 2018

Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of PROMACTA KIT before it's drug patent expiration?
More Information on Dosage

PROMACTA KIT family patents

Family Patents

34. Qtern patents expiration

QTERN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-175) Apr 05, 2019
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
New Combination(NC) Feb 27, 2020
New Strength(NS) May 02, 2022
New Indication(I-804) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of QTERN before it's drug patent expiration?
More Information on Dosage

QTERN family patents

Family Patents

35. Saxenda patents expiration

SAXENDA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs
Feb, 2023

(1 year, 3 months ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(10 months ago)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(4 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 04, 2023
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

36. Stendra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7501409 METUCHEN PHARMS Preparations for oral administration
May, 2023

(1 year, 26 days ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-282) Oct 18, 2025
New Dosing Schedule(D-140) Sep 17, 2017
New Chemical Entity Exclusivity(NCE) Apr 27, 2017

Drugs and Companies using AVANAFIL ingredient

NCE-1 date: 27 April, 2016

Market Authorisation Date: 27 April, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of STENDRA before it's drug patent expiration?
More Information on Dosage

STENDRA family patents

Family Patents

37. Tradjenta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022
M(M-121) Aug 13, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016
M(M-118) Aug 13, 2015

Drugs and Companies using LINAGLIPTIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 02 May, 2011

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonylurea; Method of treating type 2 diabetes mellitus by administering linaglipt...

Dosage: TABLET;ORAL

How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage

TRADJENTA family patents

Family Patents

38. Trijardy Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage

TRIJARDY XR family patents

Family Patents

39. Xeljanz patents expiration

XELJANZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(1 year, 2 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(1 year, 2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-879) Dec 14, 2024
New Patient Population(NPP) Sep 25, 2023
New Indication(I-761) Dec 14, 2020
M(M-135) Feb 21, 2017
New Indication(I-780) May 30, 2021
New Chemical Entity Exclusivity(NCE) Nov 06, 2017

Drugs and Companies using TOFACITINIB CITRATE ingredient

NCE-1 date: 06 November, 2016

Market Authorisation Date: 06 November, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage

XELJANZ family patents

Family Patents

40. Xeljanz Xr patents expiration

XELJANZ XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6956027 PFIZER N-terminally chemically modified protein compositions and methods
Mar, 2023

(1 year, 2 months ago)

US6965027 PFIZER Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(1 year, 2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-879) Dec 14, 2024
New Indication(I-761) Dec 14, 2020
New Chemical Entity Exclusivity(NCE) Nov 06, 2017

Drugs and Companies using TOFACITINIB CITRATE ingredient

NCE-1 date: 06 November, 2016

Market Authorisation Date: 23 February, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XELJANZ XR before it's drug patent expiration?
More Information on Dosage

XELJANZ XR family patents

Family Patents

41. Xtampza Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248195 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Jul, 2023

(10 months ago)

US10525052 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jul, 2023

(10 months ago)

US8840928 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs
Jul, 2023

(10 months ago)

US10525053 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Jul, 2023

(10 months ago)

US9763883 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jul, 2023

(10 months ago)

US9592200 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Jul, 2023

(10 months ago)

US9044398 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opiods and other drugs
Jul, 2023

(10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 26, 2019

Drugs and Companies using OXYCODONE ingredient

Market Authorisation Date: 26 April, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of XTAMPZA ER before it's drug patent expiration?
More Information on Dosage

XTAMPZA ER family patents

Family Patents

42. Xywav patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8731963

(Pediatric)

JAZZ Sensitive drug distribution system and method
Jun, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-361) Jul 21, 2027
New Indication(I-870) Aug 12, 2024
Orphan Drug Exclusivity(ODE-369) Aug 12, 2028
Orphan Drug Exclusivity(ODE-231) Jul 21, 2027
New Product(NP) Jul 21, 2023

Drugs and Companies using CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE ingredient

Market Authorisation Date: 21 July, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of XYWAV before it's drug patent expiration?
More Information on Dosage

XYWAV family patents

Family Patents

43. Yosprala patents expiration

YOSPRALA's oppositions filed in EPO
YOSPRALA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8206741 GENUS LIFESCIENCES Pharmaceutical compositions for the coordinated delivery of NSAIDs
Feb, 2023

(1 year, 3 months ago)

US6926907 GENUS LIFESCIENCES Pharmaceutical compositions for the coordinated delivery of NSAIDs
Feb, 2023

(1 year, 3 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 14, 2019

Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient

Market Authorisation Date: 14 September, 2016

Treatment: Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of YOSPRALA before it's drug patent expiration?
More Information on Dosage

YOSPRALA family patents

Family Patents